Genexa Kids' Pain & Fever Acetaminophen Liquid, Cherry, 4 fl. oz., 2 pk.

Product is FSA & HSA eligible.

Shop more FSA & HSA eligible products

• Same Active Ingredient As Children's Tylenol® Oral Suspension
• Two 4 oz bottles of cherry flavored acetaminophen oral suspension
• Starts to reduce fever in as little as 20 minutes
• Contains 160 mg of acetaminophen in each 5mL dose
• No artificial dyes, flavors, sweeteners or common allergens

Effective and Clean Pain Relief

Genexa Kids' Pain & Fever is crafted with the same potent acetaminophen found in Children's Tylenol® Oral Suspension Grape, but it excludes artificial fillers. This product is designed to temporarily reduce fever and provide relief from a variety of cold and flu symptoms. These symptoms include minor aches and pains, headaches, and sore throats.

Organic Ingredients and Flavor

This oral suspension boasts an organic cherry flavor, making it a pleasant remedy for your child's discomfort. It contains the same effective ingredient - 160 mg of acetaminophen per 5 mL - necessary for symptom relief. However, it is free from artificial sweeteners, preservatives, dyes, parabens, and common allergens. This makes it a healthier alternative for your child's needs.

Suitable for Children

Genexa Kids' Pain & Fever is suitable for use by children between the ages of 2 and 11 years. It's a reliable solution to help alleviate your child's cold and flu symptoms.

Quality Certified

All Genexa products are made in the USA with globally sourced ingredients. These products are backed by trusted certifications for your peace of mind. They're non-GMO project certified, certified gluten-free, and most products, including this one, are certified vegan. Trust Genexa for high-quality, clean, and effective symptom relief for your children.

Pediatrician Preferred Ingredients

Pediatricians were asked which ingredient profile they would choose for their own patients’ pain and fever, and they selected Genexa’s ingredients over those in the top-selling comparable products (FRC 2025).